Making rare antibody discoveries routine, and opening a new universe of transformational therapies
About Us
K2 is the second-highest mountain on Earth but the most technically challenging to climb.
We harness the power of synthetic biology and evolution to make the most challenging discoveries routine.
K2 is pioneering the next generation of antibody-based biologics targeting challenging multi-pass membrane proteins to address unmet needs in the treatment of disease.
We have developed powerful scalable yeast-based platforms for discovery, evolution, and optimization of precision antibodies. Therapeutic antibodies against multi-pass membrane targets (such as GPCRs, ion channels and solute transporters) that were previously inaccessible can now be readily generated making it possible to develop a wide range of compelling new treatment options for diseases with high unmet need.
Our Science
K2 is transforming drug discovery and development for challenging multi-pass membrane targets by combining cutting edge synthetic biology and directed-evolution technologies with established drug development expertise.
Synthetic biology circuits enable identification of rare antibodies with high scale, efficiency, and precision.
Directed evolution platforms enable affinity maturation without the constraints of a predefined library.
Unique antibodies against high-value targets enable new first and best-in-class therapeutics.
Meet the Team
-
Thomas Galbo, Ph.D.
Chief Executive Officer
-
Holger Wesche, Ph.D.
Chief Scientific Officer
-
Kevin Carlin, Ph.D.
Associate Director,
Protein Science -
Chen Fang, Ph.D.
Principal Scientist,
Protein Science -
Bryan Lemon, Ph.D.
Senior Vice President,
Product Development -
Mary Ellen Molloy, Ph.D.
Director,
In Vivo and Translational Science -
Alex Javanpour, Ph.D.
Scientist,
Synthetic Biology -
Kevin Wright, Ph.D.
Senior Director,
Research
Our Founders
-
Mo Khalil, Ph.D.
Professor,
Boston University -
Chang Liu, Ph.D.
Professor,
UC Irvine -
Nikit Patel, Ph.D.
Scientist,
Boston University -
Arjun Ravikumar, Ph.D.
Scientist,
Boston University -
Gordon Rix, Ph.D.
Scientist,
Boston University -
Brandon Wong, Ph.D.
Scientist,
Boston University
Our Board
-
Thomas Galbo, Ph.D.
Chief Executive Officer
-
Mo Khalil, Ph.D.
Professor,
Boston University -
Chang Liu, Ph.D.
Professor,
UC Irvine -
Mariana Mihalusova, Ph.D.
Venrock
-
Clayton Witter
CVF
-
Bryan Roberts, Ph.D.
Venrock,
Observer
Careers
We’re always interested in meeting motivated and talented people who want to make an impact.
We move fast, think deeply, and care about doing meaningful work together. If you’re excited about using cutting-edge science to solve big problems, then reach out to us and follow us on LinkedIn.
Investors
Contact Us
Corporate Address
K2 Therapeutics, Inc.
769 Centre Street, Suite 226
Boston, MA 02130
Research Address
K2 Therapeutics, Inc.
341 Oyster Point Blvd
South San Francisco, CA 94080
Email
info@k2-tx.com
© 2025. All Rights Reserved. Designed by Brandon Wong